curasan AG received licence for ATR®

Kleinostheim, Germany, 16 October 2009 – curasan AG, which is listed on the General Standard of the German Stock Exchange (ISIN: DE 000 549 453 8), has been received CE certification and, therefore, marketing authorization for the ATR® (Advanced Tissue Regeneration) product.

ATR® is a disposable system that is used to enrich the body’s own growth factors to a level many times higher than normal blood values. The most important areas of application are serious skin damage, such as decubitus and ulcers, large area burns, skin transplants, plastic surgery and the optimised regeneration of bone and mucous tissue.

Josh Sandberg

Josh Sandberg is the President and CEO of Ortho Spine Partners and sits on several company and industry related Boards. He also is the Creator and Editor of OrthoSpineNews.

Related Articles

Back to top button